Treatment Name: ATRA (Tretinoin) + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®)

ATRA (Tretinoin) + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®) is a Treatment Regimen for Acute Promyelocytic Leukemia (APL)

Thank you for visiting our ATRA (Tretinoin) + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®) page.

If you are interested in seeing the full treatment regimen page for ATRA (Tretinoin) + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®) sooner rather than later, please cast your vote for ATRA (Tretinoin) + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®).
Votes from users like you are important as they help us prioritize the order in which we build our content. The more requests we receive, the faster we will build it!

While we work on uploading the pages that matter to you most, we hope that links to journal article references for ATRA (Tretinoin) + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®) shown below will prove useful in the meantime.

Thank you for your continued support!

Sincerely,
The ChemoExperts Team

References

1) Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275-1283.

Created: March 7, 2019 Updated: March 7, 2019

What is Acute Promyelocytic Leukemia (APL)?

Acute Promyelocytic Leukemia (APL) is a type of acute leukemia that affects a specific type of white blood cell known as promyelocytes, which are found in the bone marrow. APL is a rare condition. The cause of APL is unknown. It can present as low, intermediate, or high-risk disease. The effectiveness of the treatment may depend upon the risk category (low, intermediate, or high) at diagnosis. APL is highly curable when appropriate treatment is not delayed.

NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose which therapy is appropriate for you.

Common ATRA + Arsenic Trioxide (Trisenox®) + Gemtuzumab Ozogamicin (Mylotarg®) starting doses

Oral ATRA (Tretinoin): 45 mg/m²/day (in two divided doses, rounded to 10 mg capsule size). ATRA is taken by mouth morning and night every day until hematologic complete remission is achieved
Arsenic Trioxide 0.15 mg/kg/day intravenous (I.V.) infusion infused over 2 hours once daily, every day, until hematologic complete remission is achieved
Gemtuzumab ozogamicin 9 mg/m² I.V. infusion over 2 hours on Day 1